A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Coronary Disease and Diabetes Mellitus, sponsored by Pfizer. Terminated at 221 sites in 7 countries. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-03.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing atorvastatin in Coronary Disease — none open to participants now, none under way, none of them phase 3. Atorvastatin · Coronary Disease.
Among the 11 studies testing atorvastatin in Coronary Disease, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2004, is one of 2 in phase 3, and was the 1st registered.
1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →None of the 11 studies testing atorvastatin in Coronary Disease is open now. The open studies under Coronary Disease, anywhere →
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 45 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2004.
This study's enrollment of 15,067 is above the median of 160 across 779 interventional studies indexed under Coronary Disease.
Median enrollment 200 across the 10 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 11 have an industry lead sponsor. The 9 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 3 studies filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing atorvastatin in Coronary Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug pages: Torcetrapib · Atorvastatin
The time to first occurrence of a major cardiovascular disease event
Various composites of major cardiovascular disease events and other lipid parameters
Showing the first 100 of 221 sites across 7 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2004, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Torcetrapib · Atorvastatin